FDA drug reviewers advise against Lilly's amyloid imaging agent
This article was originally published in Clinica
Executive Summary
Lilly's Alzheimer's disease imaging agent Amyvid (florbetapir F18) looks likely to be rejected by the US FDA. On 18 January, the agency's drug reviewers recommended against its approval, stating that data in the firm's new drug application failed to confirm the agent's efficacy in detecting beta-amyloid in the brain during positron emission tomography (PET) imaging.